CARA News and Press, Cara Therapeutics Inc. From 04/21/20

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02) Statistically significant improvement in key secondary endpoint of proportion of patients with fo...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

STAMFORD, Conn., April 08, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, to...

Following up on its initial announcements in January and February , Incyte (NASDAQ: INCY ) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2 , evaluating a topical cream formulation of kinase inhibitor ruxolitinib in adolescents and adults wi...

Cara Therapeutics (NASDAQ: CARA ): despite Covid-19 disruptions, remains on track to report topline data from the Phase 3 KALM-2 study of Korsuva (difelikefalin) in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritis (itchy skin) next quarter. It expe...

- On track to report topline data for KALM-2 Phase 3 global trial of  KORSUVA™ Injection in second quarter –                      - On track to complete interim statistical analysis for ongoing Phase 2 trial of O...

Image source: The Motley Fool. Cara Therapeutics Inc   (NASDAQ: CARA) Q4 2019 Earnings Call Feb 27, 2020 , 4:30 p.m. ET Operator Continue reading

Overview Cara Therapeutics focuses on developing therapies to treat itching, called pruritus, which is an unfortunate side effect for a lot of diseases. Cara’s late stage candidate, CR845 (Korsuva), initially targeted post-op pain. The company made the switch from focusing on pain...

Cara Therapeutics, Inc. (CARA) Q4 2019 Earnings Conference Call February 27, 2020 04:30 PM ET Company Participants Jack Hildick-Smith - Stern Investor Relations Derek Chalmers - President and Chief Executive Officer Rick Makara - Vice President and Head, Accounting Conference ...

Cara Therapeutics (NASDAQ: CARA ): Q4 GAAP EPS of -$0.61 beats by $0.03 . Revenue of $4.5M (-18.6% Y/Y) misses by $0.89M . Press Release More news on: Cara Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,